CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...